Institute of Oncology, Shandong Provincial Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China.
Department of Oncology, Shandong Provincial Hospital affiliated to Shandong First Medical University, Jinan, China.
Front Immunol. 2022 Aug 11;13:960738. doi: 10.3389/fimmu.2022.960738. eCollection 2022.
Glutamine (Gln) metabolism has been reported to play an essential role in cancer. However, a comprehensive analysis of its role in lung adenocarcinoma is still unavailable. This study established a novel system of quantification of Gln metabolism to predict the prognosis and immunotherapy efficacy in lung cancer. Further, the Gln metabolism in tumor microenvironment (TME) was characterized and the Gln metabolism-related genes were identified for targeted therapy.
We comprehensively evaluated the patterns of Gln metabolism in 513 patients diagnosed with lung adenocarcinoma (LUAD) based on 73 Gln metabolism-related genes. Based on differentially expressed genes (DEGs), a risk model was constructed using Cox regression and Lasso regression analysis. The prognostic efficacy of the model was validated using an individual LUAD cohort form Shandong Provincial Hospital, an integrated LUAD cohort from GEO and pan-cancer cohorts from TCGA databases. Five independent immunotherapy cohorts were used to validate the model performance in predicting immunotherapy efficacy. Next, a series of single-cell sequencing analyses were used to characterize Gln metabolism in TME. Finally, single-cell sequencing analysis, transcriptome sequencing, and a series of experiments were used to explore the role of EPHB2 in LUAD.
Patients with LUAD were eventually divided into low- and high-risk groups. Patients in low-risk group were characterized by low levels of Gln metabolism, survival advantage, "hot" immune phenotype and benefit from immunotherapy. Compared with other cells, tumor cells in TME exhibited the most active Gln metabolism. Among immune cells, tumor-infiltrating T cells exhibited the most active levels of Gln metabolism, especially CD8 T cell exhaustion and Treg suppression. EPHB2, a key gene in the model, was shown to promote LUAD cell proliferation, invasion and migration, and regulated the Gln metabolic pathway. Finally, we found that EPHB2 was highly expressed in macrophages, especially M2 macrophages. It may be involved in the M2 polarization of macrophages and mediate the negative regulation of M2 macrophages in NK cells.
This study revealed that the Gln metabolism-based model played a significant role in predicting prognosis and immunotherapy efficacy in lung cancer. We further characterized the Gln metabolism of TME and investigated the Gln metabolism-related gene EPHB2 to provide a theoretical framework for anti-tumor strategy targeting Gln metabolism.
谷氨酰胺(Gln)代谢已被报道在癌症中发挥重要作用。然而,其在肺腺癌中的作用仍缺乏全面分析。本研究建立了一种新的 Gln 代谢定量分析系统,以预测肺癌的预后和免疫治疗疗效。此外,还对肿瘤微环境(TME)中的 Gln 代谢进行了特征分析,并确定了用于靶向治疗的 Gln 代谢相关基因。
我们基于 73 个 Gln 代谢相关基因,对 513 例肺腺癌(LUAD)患者的 Gln 代谢模式进行了全面评估。基于差异表达基因(DEGs),使用 Cox 回归和 Lasso 回归分析构建风险模型。使用来自山东省立医院的个体 LUAD 队列、GEO 整合 LUAD 队列和 TCGA 数据库的泛癌队列对模型的预后效能进行验证。使用 5 个独立的免疫治疗队列验证模型在预测免疫治疗疗效方面的性能。接下来,我们使用一系列单细胞测序分析来描述 TME 中的 Gln 代谢。最后,使用单细胞测序分析、转录组测序和一系列实验来探索 EPHB2 在 LUAD 中的作用。
LUAD 患者最终被分为低风险组和高风险组。低风险组患者的 Gln 代谢水平较低,生存优势明显,表现出“热”免疫表型,且能从免疫治疗中获益。与其他细胞相比,TME 中的肿瘤细胞表现出最活跃的 Gln 代谢。在免疫细胞中,肿瘤浸润 T 细胞表现出最活跃的 Gln 代谢水平,尤其是 CD8 T 细胞耗竭和 Treg 抑制。模型中的关键基因 EPHB2 被证明可促进 LUAD 细胞的增殖、侵袭和迁移,并调节 Gln 代谢途径。最后,我们发现 EPHB2 在巨噬细胞中高表达,特别是 M2 巨噬细胞。它可能参与巨噬细胞的 M2 极化,并介导 M2 巨噬细胞对 NK 细胞的负调控。
本研究揭示了基于 Gln 代谢的模型在预测肺癌预后和免疫治疗疗效方面具有重要作用。我们进一步对 TME 中的 Gln 代谢进行了特征分析,并研究了与 Gln 代谢相关的基因 EPHB2,为靶向 Gln 代谢的抗肿瘤策略提供了理论框架。